In this review:
This review is intended as an educational resource for health professionals. It presents a concise
background on myelodysplastic syndrome (MDS), including its prognosis and clinical management.
In terms of treatment, the review highlights two newer pharmacological agents available, lenalidomide
and azacitidine, approved by Medsafe for low-risk MDS and high-risk MDS, respectively.
Download PDF